0001193125-26-093917
SEC filingEyePoint Pharmaceuticals, Inc. reported a net loss of $232.0 million for fiscal year 2025, driven by a significant loss from operations of $243.4 million. Total revenues were $31.4 million, derived entirely from product sales, license and collaboration agreements, and royalty income. Operating expenses totaled $274.8 million, with research and development costs of $221.0 million being the primary expense. The company ended the year with total assets of $364.0 million, including $101.8 million in cash and cash equivalents and $204.3 million in marketable securities. Total liabilities were $57.9 million, resulting in stockholders' equity of $306.1 million. Cash used in operating activities was $240.1 million, while net cash provided by financing activities was $173.6 million, primarily from stock issuance. The company acknowledges it has incurred significant losses and will likely need additional capital to fund operations.
EyePoint Pharmaceuticals reported a net loss of $232.0 million for the fiscal year ended December 31, 2025, compared to a net loss of $232.0 million as indicated in the accumulated deficit line. Total revenues were $31.4 million, consisting entirely of product sales, net of $31.4 million, license and collaboration agreements of $31.4 million, and royalty income of $31.4 million. The loss from operations was $243.4 million, primarily due to high operating expenses of $274.8 million, which included research and development costs of $221.0 million and general and administrative expenses of $51.6 million. Other income, net, provided $11.8 million, largely from interest and other income.
Total revenues for FY 2025 were $31.4 million. The revenue breakdown shows product sales, net of $31.4 million, license and collaboration agreements of $31.4 million, and royalty income of $31.4 million. Geographically, revenues were reported as $31.4 million from the US, $31.4 million from China, and $31.4 million from the United Kingdom. Key revenue drivers included agreements with ANI Pharmaceuticals, Inc. and Ocumension Therapeutics, contributing to product sales and license revenues. The company's revenue is heavily reliant on these collaborations and product rights agreements.
The company reported a gross profit of $29.3 million, calculated as total revenues of $31.4 million minus cost of sales of $2.1 million, resulting in a gross margin of 93.3%. However, operating expenses of $274.8 million led to an operating loss of $243.4 million and an operating margin of -775.2%. Research and development expenses of $221.0 million were the largest cost component, reflecting significant investment in clinical development, particularly for the lead product candidate DURAVYU. General and administrative expenses were $51.6 million, while sales and marketing expenses were minimal at $90,000.
Net cash used in operating activities was $240.1 million, driven by the net loss of $232.0 million and adjustments including stock-based compensation of $27.9 million. Cash flows from investing activities provided $68.6 million, mainly from net sales and maturities of marketable securities. Cash flows from financing activities provided $173.6 million, primarily from proceeds from issuance of stock of $173.4 million. The balance sheet shows total assets of $364.0 million, with current assets of $328.7 million including cash and cash equivalents of $101.8 million and marketable securities of $204.3 million. Total liabilities were $57.9 million, with current liabilities of $37.0 million. Stockholders' equity was $306.1 million.
The company acknowledges in its risk factors that it has incurred significant losses since inception and anticipates continuing losses for the foreseeable future. It states that it will likely need additional capital to fund operations, which may not be available on favorable terms and could be dilutive to stockholders. Key strategic priorities include the clinical development and regulatory approval of its lead product candidate, DURAVYU, for wet AMD and DME. Risks include potential delays in clinical trials, regulatory challenges, dependence on third-party suppliers, and intellectual property protection. The company also notes a pending DOJ investigation that could materially impact its business if not resolved favorably.